Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ISonea Granted U.S. Patent For Cough Count Technology

iSonea (ASX: ISN, OTCQX: ISOAY) has secured a U.S. patent covering its ultrasound-based cough detector that fits against a patient's neck and automatically detects coughs and counts coughing events.

Importantly, this latest award builds on the company's growing patent portfolio that contains more than 15 issued patents and numerous patent applications centred on respiratory diseases and sound analysis.

iSonea has been working with the United States Patent and Trademark Office over the past several months to finalise the latest patent for cough detection.

Chief executive officer Michael Thomas said, "Combining the company's active and passive acoustic technologies and expertise, the technology provides a meaningful way to quantify this important symptom, which will aid clinicians in the diagnosis and treatment of several diseases and respiratory conditions."

The sensors on the device can detect high and low frequency mechanical vibrations in the tracheal area.

The device senses coughing events, tracks their severity and duration, and stores that data or sends it wirelessly to a computer or other log.

Cough is an important symptom used in many assessment standards for the diagnosis and treatment of diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis and gastroesophageal reflux disease, among others.

Strengthening Medical Advisory Board

Earlier this month iSonea appointed Lynn Taussig to chair its Medical Advisory Board.

Taussig is a renowned authority on asthma and is the author of more than 180 scientific publications and six books and monographs.

He was the chair of the Steering Committee of the National Institute of Health's Childhood Asthma Research and Education Network for 11 years.

He currently chairs another steering committee and two Data Safety Monitoring Boards for the National Institute of Health's National Heart, Lung and Blood Institute.

iSonea's Medical Advisory Board will advise the company on clinical studies related to the commercial development of its Acoustic Respiratory Monitoring devices and mobile health applications for the management of asthma and related respiratory disorders.